carboplatin + methotrexate + mitoxantrone + vincristine

This is a combination chemotherapy regimen consisting of four cytotoxic agents: carboplatin, methotrexate, mitoxantrone, and vincristine. The regimen has been studied under the names MIMOC (Mitoxantrone, Methotrexate, Vincristine and Carboplatin) in advanced breast cancer and MCNO (Methotrexate, Carboplatin, Mitoxantrone and Vincristine) in transitional cell urothelial cancer. Each component acts via a distinct mechanism: - **Carboplatin** is a platinum-based compound that forms DNA crosslinks leading to apoptosis. - **Methotrexate** is an antimetabolite that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis. - **Mitoxantrone** intercalates into DNA and inhibits topoisomerase II activity. - **Vincristine** binds tubulin to inhibit microtubule formation during mitosis. The combination has demonstrated efficacy as first-line therapy for advanced breast cancer with notable response rates[1], as well as activity in locally advanced or metastatic transitional cell carcinoma of the bladder[2]. Toxicities are generally manageable but can include nausea/vomiting and myelosuppression.

Other names

MIMOCMCNO